Rar selective agonists in combination with immune modulators for cancer immunotherapy
AssigneeIo Therapeutics, Inc.
InventorsRoshantha A. Chandraratna, Martin E. Sanders
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Claims21
1-30. (canceled)
A method of potentiating immune checkpoint inhibitor therapy comprising administering at least one differentiating retinoic acid receptor (RAR) active agent, wherein the differentiating RAR active agent is a RARα agonist, to a cancer patient who is receiving or is scheduled to receive, an immune checkpoint inhibitor antibody, wherein the RARα agonist is a CYP26 metabolism-resistant, RARα selective agonist having a structure of general formula (I)
- wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen.
A method of cancer immunotherapy comprising administering to a subject in need thereof an immune checkpoint inhibitor antibody and at least one differentiating RAR active agent, wherein the differentiating RAR active agent is a RARα agonist, wherein the RARα agonist is a CYP26 metabolism-resistant, RARα selective agonist having a structure of general formula (I)
- wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen.
The method according to claim 1, wherein R4 is F, Cl, Br or I.
The method according to claim 2, wherein R4 is F, Cl, Br or I.
Dependencies are inferred from the claim text.